Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 9
Submit an article Journal homepage
346
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses

Justin R. ArnallDepartment of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA; View further author information
,
Donald C. MooreDepartment of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA; Correspondence[email protected]
View further author information
,
Hailey L. HillDepartment of Pharmacy, Atrium Health, Carolinas Medical Center, Charlotte, NC, USA; View further author information
,
Sarah GriffinInova Fairfax Hospital, Falls Church, VA, USA; View further author information
,
Maxine K. MuellerDepartment of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA; View further author information
,
Lesli A. LaveryDepartment of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA; View further author information
,
Peter M. VoorheesDepartment of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute, Charlotte, NC, USAView further author information
&
Saad Z. UsmaniDepartment of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute, Charlotte, NC, USAView further author information
 show all
Pages 2295-2298 | Received 18 Oct 2018, Accepted 22 Jan 2019, Published online: 08 Mar 2019

References

  • Lonial S, Weis BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560.
  • Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331.
  • Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766.
  • Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130:974–981.
  • Darzalex (daratumumab) [prescribing information]. Horsham (PA): Janssen Biotech, Inc; 2017.
  • Chari A, Mark TM, Krishnan A, et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Blood. 2019;128:2142.
  • Usmani SZ, Jakubowiak A, Chari A, et al. Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM). Ann Oncol. 2017;28:v355–v371.
  • Xu S, Moreau P, Usmani SZ, et al. Split first dose administration of daratumumab for the treatment of patients with multiple myeloma (MM): clinical pharmacology and population pharmacokinetic analyses (PK). Blood. 2018;653:1970.
  • Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518–528.
  • Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–1219.
  • Cejalvo MJ, Legarda M, Abella E, et al. Activity and safety of daratumumab monotherapy in patients in relapsed and refractory multiple myeloma requiring dialysis: preliminary results of Spanish, retrospective, multicenter trial. Blood. 2017;130:1866.
  • Rocchi S, Tacchetti P, Pantani L, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica. 2018;103:e277–e278.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.